Last reviewed · How we verify

Placebo followed by Ondansetron

University of Colorado, Denver · Phase 3 active Small molecule

Placebo followed by Ondansetron is a 5-HT3 receptor antagonist Small molecule drug developed by University of Colorado, Denver. It is currently in Phase 3 development for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting. Also known as: Zofran, Zuplenz.

Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting. Used for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

At a glance

Generic namePlacebo followed by Ondansetron
Also known asZofran, Zuplenz
SponsorUniversity of Colorado, Denver
Drug class5-HT3 receptor antagonist
Target5-HT3 receptor
ModalitySmall molecule
Therapeutic areaSupportive Care / Antiemetic
PhasePhase 3

Mechanism of action

Ondansetron is a selective antagonist of serotonin 5-HT3 receptors, which are located on chemoreceptor trigger zone neurons and on the vagal afferent nerves of the gastrointestinal tract. By blocking these receptors, it prevents the transmission of emetic signals to the vomiting center in the brainstem. This mechanism makes it particularly effective for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo followed by Ondansetron

What is Placebo followed by Ondansetron?

Placebo followed by Ondansetron is a 5-HT3 receptor antagonist drug developed by University of Colorado, Denver, indicated for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

How does Placebo followed by Ondansetron work?

Ondansetron blocks serotonin 5-HT3 receptors on chemoreceptor trigger zone and vagal afferent nerves to prevent nausea and vomiting.

What is Placebo followed by Ondansetron used for?

Placebo followed by Ondansetron is indicated for Prevention of nausea and vomiting induced by chemotherapy, Prevention of postoperative nausea and vomiting, Prevention of radiation-induced nausea and vomiting.

Who makes Placebo followed by Ondansetron?

Placebo followed by Ondansetron is developed by University of Colorado, Denver (see full University of Colorado, Denver pipeline at /company/university-of-colorado-denver).

Is Placebo followed by Ondansetron also known as anything else?

Placebo followed by Ondansetron is also known as Zofran, Zuplenz.

What drug class is Placebo followed by Ondansetron in?

Placebo followed by Ondansetron belongs to the 5-HT3 receptor antagonist class. See all 5-HT3 receptor antagonist drugs at /class/5-ht3-receptor-antagonist.

What development phase is Placebo followed by Ondansetron in?

Placebo followed by Ondansetron is in Phase 3.

What are the side effects of Placebo followed by Ondansetron?

Common side effects of Placebo followed by Ondansetron include Headache, Constipation, Diarrhea, Fatigue, Dizziness.

What does Placebo followed by Ondansetron target?

Placebo followed by Ondansetron targets 5-HT3 receptor and is a 5-HT3 receptor antagonist.

Related